INCY
Incyte Corp.

5,601
Mkt Cap
$20.85B
Volume
1.7M
52W High
$112.29
52W Low
$53.56
PE Ratio
17.82
INCY Fundamentals
Price
$106.21
Prev Close
$105.24
Open
$105.55
50D MA
$102.47
Beta
0.52
Avg. Volume
2.09M
EPS (Annual)
$0.1549
P/B
4.48
Rev/Employee
$1.62M
Loading...
Loading...
News
all
press releases
29,222 Shares in Incyte Corporation $INCY Bought by Campbell & CO Investment Adviser LLC
Campbell & CO Investment Adviser LLC acquired a new position in Incyte Corporation (NASDAQ:INCY - Free Report) in the third quarter, according to the company in its most recent disclosure with the...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
GRIMES & Co WEALTH MANAGEMENT LLC Sells 16,883 Shares of Incyte Corporation $INCY
GRIMES & Co WEALTH MANAGEMENT LLC reduced its holdings in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 9.4% during the third quarter, according to its most recent 13F filing with the...
MarketBeat·4d ago
News Placeholder
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·5d ago
News Placeholder
Bull of the Day: Eli Lilly (LLY)
Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.
Zacks·8d ago
News Placeholder
Incyte (NASDAQ:INCY) Price Target Raised to $94.00
Morgan Stanley raised their price target on shares of Incyte from $92.00 to $94.00 and gave the company an "equal weight" rating in a research report on Tuesday...
MarketBeat·11d ago
News Placeholder
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Zacks·11d ago
News Placeholder
Robeco Institutional Asset Management B.V. Has $196.71 Million Stake in Incyte Corporation $INCY
Robeco Institutional Asset Management B.V. cut its position in Incyte Corporation (NASDAQ:INCY - Free Report) by 2.8% in the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·11d ago
News Placeholder
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified...
Business Wire·12d ago
News Placeholder
CWA Asset Management Group LLC Acquires New Holdings in Incyte Corporation $INCY
CWA Asset Management Group LLC bought a new position in Incyte Corporation (NASDAQ:INCY - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional...
MarketBeat·12d ago
News Placeholder
Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY
Financiere des Professionnels Fonds d investissement inc. bought a new stake in shares of Incyte Corporation (NASDAQ:INCY - Free Report) during the third quarter, according to the company in its most...
MarketBeat·13d ago
<
1
2
...
>

Latest INCY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.